目的探讨纤溶酶原激活物抑制物-1（PAI- 1）启动子区基因多态性与脑卒中的关系。
Objective To investigate the relationship between the plasminogen activator inhibitor 1(PAI 1) promotor region gene polymorphism and cerebral stroke.
用酶联免疫吸附法检测血浆血管性假性血友病因子、凝血酶调节蛋白、纤溶酶原激活物抑制物1水平。
The von Willebrand's disease factors in plasm, adjusted protein of thrombase and inhibitor 1 of activator of plasminogen were detected with enzyme-linked immunosorbent assay.
目的：探讨纤溶酶原激活物抑制物-1 (PAI - 1)活性变化和其基因多态性对脑梗死及其再梗死发病的关系。
To investigate the changes of plasma PAI 1 activity and its gene polymorphism in cerebral infarction.
目的：观察银杏叶提取物对2型糖尿病病人纤溶酶原激活物抑制物1（PAI 1）及凝血烷B2（TXB 2 ）的影响。
AIM: To observe the effect of extract of Ginkgo biloba leaves on plasminogen activator inhibitor 1(PAI-1)and thromboxane B2(TXB-2)in type 2 diabetes mellitus(DM).
方法：检测33例糖尿病肾病患者及30例健康体检对照组血浆纤溶酶原激活物抑制物-1（PAI-1），观察检测结果。
Method Plasminogen activator inhibitor-1(PAI-1) in 33 cases of diabetic nephropathy and 30 healthy controls were detected, and the test results were observed.
纤溶酶原激活物抑制物1 (PAI - 1)是血浆纤维蛋白溶解系统的重要组成物之一，对维持血浆纤溶系统的稳定起重要作用。
Plasminogen activator inhibitor-1 (PAI-1) is one of the important components of the plasma fibrinolytic system and plays an key role in maintaining its stability.
目的：探讨急性冠脉综合征患者应用阿托伐他汀调脂治疗后对血管内皮舒张功能、血浆纤溶酶原激活物抑制物1及血管内皮素1的影响。
Objective To study the effects of atorvastatin cholesterol-lowering therapy on vascular endothelial function and plasminogen activator inhibitor-1 in acute coronary syndromes.
目的通过对动脉粥样硬化（AS）兔血清和粥样硬化斑块中纤溶酶原激活物抑制物-1（PAI-1）表达的研究，探讨PAI-1在AS中的作用。
Objective To study the expression of plasminogen activator inhibitor-1(PAI-1) of the blood serum and plaques in atherosclerotic rabbits in order to explore the effect of PAI-1 on atherosclerosis (AS).
目的探讨血浆组织型纤溶酶原激活物(t -PA)及其抑制物(PAI - 1)在急性脑梗死发病中的意义。
Objective To assess the clinical significance of plasma t-PA, PAI-1 in acute cerebral infarction.
结论：糖尿病肾病患者存在血浆纤溶酶原激活物及其抑制物系统失衡。
Conclusion The diabetic nephropathy patients have imbalance of plasma plasminogen activator and its inhibitor system.
结论：糖尿病肾病患者存在血浆纤溶酶原激活物及其抑制物系统失衡。
Conclusion The diabetic nephropathy patients have imbalance of plasma plasminogen activator and its inhibitor system.
应用推荐